We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Real-Time Glucose Saliva-Based Test to Replace Invasive Finger-Prick Testing for Diabetic Patients

By LabMedica International staff writers
Posted on 21 Oct 2021
Print article
Image: The Saliva Glucose Biosensor (Photo courtesy of GBS, Inc.)
Image: The Saliva Glucose Biosensor (Photo courtesy of GBS, Inc.)

A non-invasive, real-time saliva-based glucose test for patients and their primary health practitioners at point-of-care could provide people living with diabetes a more favorable solution to finger-prick blood glucose testing.

GBS, Inc. (New York, NY, USA) is developing a saliva-based glucose test on the Biosensor Platform to be used in the point-of-care setting. The company has filed a Pre-Submission package with the US Food and Drug Administration (FDA) to confirm that it is following the proper steps to conduct the clinical studies enabling it to develop the glucose biosensor according to the FDA regulatory standards. The Biosensor Platform is a small, printable organic strip designed to put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners. By altering the detection element depending on the specific analyte of interest, GBS has the ability to produce a whole portfolio of non-invasive, real-time, saliva-based diagnostic tests. Because both the core OTFT sensing element and the mechanism of action remains the same, tests developed from the Biosensor Platform have the potential to be printed at scale, at a low cost.

The real-time saliva-based glucose test offers a pain-free option to current testing methods by using an organic thin film transistor, incorporating Glucose Oxidase (GOX) as the recognition element to initiate an electrochemical reaction that produces an electrical signal to display glucose measurements in real-time on a mobile app or dedicated device. The Saliva Glucose Biosensor is the first non-invasive, saliva-based glucose test for diabetes management that measures glucose in saliva, not blood. The innovative technology will free people living with diabetes from having to use painful and invasive blood monitoring devices to manage their condition, giving them a better quality of life.

The Saliva Glucose Biosensor System will allow the patient to achieve better glucose control through a practical understanding of lifestyle factors that affect glucose levels, thereby helping prevent or delay diabetes complications and ultimately personalizing diabetes management. At the patient’s or authorized carer’s requirement, the patient data can be disseminated to a remote caregiver, a service for consultation or to any other individual with whom the patient chooses to share their glucose level measurements. Through the regulatory process GBS intends to demonstrate that the Saliva Glucose Biosensor can be used as a point of care self-test, indicated for the management of diabetes, non-adjunctive to blood glucose testing for diabetes treatment decisions.

 “The number of people living with diabetes is expected to increase to 700 million by 2045 and in 2019 an estimated 1.5 million deaths were directly caused by this disease, so it is imperative people living with diabetes have the means to regularly monitor and manage their glucose levels in a painless and easy way,” said Harry Simeonidis Chief Executive Officer of GBS. “It has always been our mission to create simple to use, life-changing diagnostics that can be put into the hands of people who need them the most, and our world-first Biosensor technology is the first step in fulfilling that mission.”

Related Links:
GBS, Inc. 

Gold Supplier
SARS-CoV-2 IgM ELISA Kit
SARS-CoV-2 (COVID-19) IgM ELISA
New
Automated R-AST Solution
Radian BC
New
Silver Supplier
Helicobacter Pylori Test
AB HP UREASE TEST
New
Gold Supplier
Chemistry Analyzer
BS-600M

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.